Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Expected to Announce Quarterly Sales of $99.35 Million

Brokerages expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) to report $99.35 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Harmony Biosciences’ earnings. The highest sales estimate is $100.50 million and the lowest is $96.88 million. Harmony Biosciences posted sales of $73.82 million in the […]

Related Keywords

United States ,Jack Nielsen ,Andreas Wicki ,Polar Capital Holdings Plc ,Zacks Investment Research ,Harmony Biosciences Company Profile Get Rating ,Blackrock Inc ,Nasdaq ,Cantor Fitzgerald ,Harmony Biosciences Holdings Inc ,Valor Management ,Harmony Biosciences Holdings ,Get Rating ,Harmony Bioscience ,Harmony Biosciences ,Investment Research ,Director Andreas Wicki ,Director Jack Nielsen ,Capital Holdings Plc ,Capital Partners ,State Street Corp ,Street Corp ,Biosciences Company Profile ,Biosciences Holdings ,Nasdaq Hrmy ,Thrmy ,Medical ,Ratings ,Consensus ,